drugset / Trial / NCT02000362
Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of phase I clinical trial is to evaluate safety and efficacy in subjects with moderately active Crohn's disease after injection for 28days. The purpose of phase IIa clinical trial is to determine therapeutic safety and efficacy of FURESTEM-CD Inj. which is based on Crohn's disease activity index(CDAI)\<150 after injection.
Timeline
- Start
- 2014-08
- Primary completion
- 2018-09
- Completion
- 2018-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rexlemestrocel-L | Cell therapy | 5e+07 cells | — |
| Subject | Rexlemestrocel-L | Cell therapy | 1e+08 cells | — |